{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:20:48Z","timestamp":1790763648496,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1007\/s40265-019-01070-8","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T02:22:13Z","timestamp":1550542933000},"page":"463-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Mirogabalin: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"key":"1070_CR1","unstructured":"Best Practice Advocacy Centre New Zealand. Managing patients with neuropathic pain. 2016. \nhttps:\/\/bpac.org.nz\/bpj\/2016\/may\/pain.aspx\n\n. Accessed 22 Jan 2019."},{"key":"1070_CR2","unstructured":"National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in nonspecialist settings. 2013. \nhttps:\/\/www.nice.org.uk\n\n. Accessed 22 Jan 2019."},{"key":"1070_CR3","unstructured":"Scottish Intercollegiate Guidelines Network. Management of chronic pain. A national clinical guideline. 2013. \nhttp:\/\/www.sign.ac.uk\n\n. Accessed 22 Jan 2019."},{"issue":"2","key":"1070_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162\u201373.","journal-title":"Lancet Neurol."},{"issue":"6","key":"1070_CR5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.bja.2018.02.066","volume":"120","author":"M Chincholkar","year":"2018","unstructured":"Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018;120(6):1315\u201334.","journal-title":"Br J Anaesth."},{"issue":"6","key":"1070_CR6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.4161\/chan.4.6.12869","volume":"4","author":"J Park","year":"2010","unstructured":"Park J, Luo ZD. Calcium channel functions in pain processing. Channels. 2010;4(6):510\u20137.","journal-title":"Channels."},{"key":"1070_CR7","unstructured":"Daiichi Sankyo Company. Tarlige\u00ae Tablets: prescribing information 2019. \nhttp:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/430574_11900B0F1020_1_02.pdf\n\n Accessed 14 Jan 2019."},{"key":"1070_CR8","unstructured":"Daiichi Sankyo Company. Daiichi Sankyo announces marketing approval in Japan of \u201cTarlige\u00ae Tablets\u201d for pain treatment [media release]. 8 Jan 2019."},{"key":"1070_CR9","unstructured":"Daiichi Sankyo Company. Consolidated financial results for Q4 FY2017. 2018. In: \nhttps:\/\/www.daiichisankyo.com\/media_investors\/investor_relations\/ir_calendar\/files\/005385\/Reference%20Data.pdf\n\n. Accessed 22 Jan 2018"},{"key":"1070_CR10","unstructured":"Daiichi Sankyo Company. Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes [media release]. 30 Jun 2017."},{"key":"1070_CR11","unstructured":"European Patent Office. European patent specification. Application number: 08833399.2. 2008. \nhttps:\/\/patentimages.storage.googleapis.com\/fb\/8b\/48\/462137eb934a5d\/EP2192109B1.pdf\n\n. Accessed 22 Jan 2019."},{"key":"1070_CR12","unstructured":"United States Patent and Trademark Office. Patent No.: US 7,947,738 B2. 2011. \nhttps:\/\/patentimages.storage.googleapis.com\/c3\/f8\/b9\/191405f3ffb709\/US7947738.pdf\n\n. Accessed 22 Jan 2019."},{"issue":"3","key":"1070_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365(3):573\u201382.","journal-title":"J Pharmacol Exp Ther."},{"issue":"46","key":"1070_CR14","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, et al. Identification of the \u03b12-\u03b4-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103(46):17537\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1070_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0002-9440(10)63362-7","volume":"165","author":"SV Ivanov","year":"2004","unstructured":"Ivanov SV, Ward JM, Tessarollo L, et al. Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene. Am J Pathol. 2004;165(3):1007\u201318.","journal-title":"Am J Pathol."},{"issue":"11","key":"1070_CR16","first-page":"659","volume":"73","author":"Y Domon","year":"2018","unstructured":"Domon Y, Kitano Y, Makino M. Analgesic effects of the novel alpha2delta ligand mirogabalin in a rat model of spinal cord injury. Pharmazie. 2018;73(11):659\u201361.","journal-title":"Pharmazie."},{"key":"1070_CR17","unstructured":"Domon Y, Arakawa N, Murasawa H, et al. Anxiolytic effects of the novel \u03b12\u03b4 ligand mirogabalin (DS-5565) in Sluka model, an experimental animal model of fibromyalgia [abstract no. 374]. Arthritis Rheumatol. 2016;68 (Suppl 10):476\u20138."},{"issue":"6","key":"1070_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cpdd.448","volume":"7","author":"M Jansen","year":"2018","unstructured":"Jansen M, Warrington S, Dishy V, et al. A randomized, placebo-controlled, double-blind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharmacol Drug Dev. 2018;7(6):661\u20139.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"1070_CR19","doi-asserted-by":"publisher","first-page":"e00418","DOI":"10.1002\/prp2.418","volume":"6","author":"K Brown","year":"2018","unstructured":"Brown K, Mendell J, Ohwada S, et al. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res Perspect. 2018;6(5):e00418.","journal-title":"Pharmacol Res Perspect."},{"issue":"1","key":"1070_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jcph.974","volume":"58","author":"M Kato","year":"2018","unstructured":"Kato M, Tajima N, Shimizu T, et al. Pharmacokinetics and safety of a single oral dose of mirogabalin in Japanese subjects with varying degrees of renal impairment. J Clin Pharmacol. 2018;58(1):57\u201363.","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"1070_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/jcph.584","volume":"56","author":"OQ Yin","year":"2016","unstructured":"Yin OQ, Merante D, Truitt K, et al. Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. J Clin Pharmacol. 2016;56(2):203\u201312.","journal-title":"J Clin Pharmacol."},{"issue":"11","key":"1070_CR22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40261-018-0692-7","volume":"38","author":"K Duchin","year":"2018","unstructured":"Duchin K, Senaldi G, Warren V, et al. Open-label single-dose study to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of mirogabalin. Clin Drug Investig. 2018;38(11):1001\u20139.","journal-title":"Clin Drug Investig."},{"key":"1070_CR23","unstructured":"Brown K, Kumagae Y, Ohwada S, et al. A multiple ascending-dose study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of mirogabalin in healthy elderly subjects [abstract no. 1443]. In: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting. 2015."},{"issue":"10","key":"1070_CR24","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1111\/bcp.13674","volume":"84","author":"M Tachibana","year":"2018","unstructured":"Tachibana M, Yamamura N, Atiee GJ, et al. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: a phase 1, randomized, open-label, drug-drug interaction study. Br J Clin Pharmacol. 2018;84(10):2317\u201324.","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"1070_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/cpdd.582","volume":"7","author":"M Jansen","year":"2018","unstructured":"Jansen M, Mendell J, Currie A, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of mirogabalin when coadministered with lorazepam, zolpidem, tramadol, or ethanol: results from drug-drug interaction studies in healthy subjects. Clin Pharmacol Drug Dev. 2018;7(6):597\u2013612.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1070_CR26","doi-asserted-by":"publisher","unstructured":"Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. J Diabetes Investig. 2019. \nhttps:\/\/doi.org\/10.1111\/jdi.13013\n\n.","DOI":"10.1111\/jdi.13013"},{"key":"1070_CR27","unstructured":"Daiichi Sankyo Company. Daiichi Sankyo announces positive top-line results from phase 3 clinical trial evaluating mirogabalin in diabetic peripheral neuropathic pain [media release]. 31 Aug 2017."},{"issue":"12","key":"1070_CR28","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2337\/dc14-1044","volume":"37","author":"A Vinik","year":"2014","unstructured":"Vinik A, Rosenstock J, Sharma U, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37(12):3253\u201361.","journal-title":"Diabetes Care."},{"issue":"11","key":"1070_CR29","first-page":"2198","volume":"18","author":"D Merante","year":"2017","unstructured":"Merante D, Rosenstock J, Sharma U, et al. Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study. Pain Med. 2017;18(11):2198\u2013207.","journal-title":"Pain Med."},{"key":"1070_CR30","doi-asserted-by":"publisher","unstructured":"Kato J, Matsui N, Kakehi Y, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019. \nhttps:\/\/doi.org\/10.1097\/j.pain.0000000000001501\n\n.","DOI":"10.1097\/j.pain.0000000000001501"},{"key":"1070_CR31","unstructured":"Daiichi Sankyo Company. Daiichi Sankyo announces first patients in large-scale, multi-national phase 3 clinical programs for mirogabalin [media release]. 4 Feb 2015."},{"key":"1070_CR32","unstructured":"Mendell J, Cooperman N, Sellers E, et al. Abuse potential of mirogabalin in recreational polydrug users [abstract no. PII-148]. Clin Pharmacol Ther. 2018;103 (Suppl 1):S94."}],"updated-by":[{"DOI":"10.1007\/s40265-019-01082-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01070-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01070-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01070-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T14:25:23Z","timestamp":1599229523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01070-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,3,1]]}},"alternative-id":["1070"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01070-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-019-01082-4","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"assertion":[{"value":"19 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The title, which currently reads:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}